PharmAthene To Host Third Quarter 2009 Conference Call and Webcast on Thursday, November 12, 2009

November 3, 2009

ANNAPOLIS, Md., Nov. 3 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the third quarter of 2009 will be released on Thursday, November 12, 2009.

PharmAthene management will be hosting a conference call to discuss its third quarter 2009 financial results. The call is scheduled to begin at 11:00 a.m. Eastern Time on Thursday, November 12, 2009, and is expected to last approximately 45 minutes.

The dial-in number within the United States is 866-700-7173. The dial-in number for international callers is 617-213-8838. The participant pass code is 45158592.

A replay of the conference call will be available beginning at approximately 2:00 p.m. Eastern Time on November 12, 2009 until approximately 11:59 p.m. Eastern Time on December 12, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant pass code is 97434742.

The conference call will also be webcast and can be accessed from the company's website at www.PharmAthene.com. A link to the webcast may be found under the Investor Relations section of the website. The web cast will be available for 30 days, or until approximately December 12, 2009.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.

PharmAthene's lead product development programs include:

    --  SparVax(TM) - a second generation recombinant protective antigen (rPA)
        anthrax vaccine
    --  Third generation rPA anthrax vaccine
    --  Valortim® - a fully human monoclonal antibody for the prevention and
        treatment of anthrax infection
    --  Protexia® - a novel bioscavenger for the prevention and treatment of
        morbidity and mortality associated with exposure to chemical nerve
        agents

    --  RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

    Contact:

    Stacey Jurchison
    PharmAthene, Inc.
    Phone: 410-269-2610
    Stacey.Jurchison@PharmAthene.com

SOURCE PharmAthene, Inc.